The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 08, 2015

Filed:

Sep. 26, 2013
Applicant:

Onyx Therapeutics, Inc., South San Francisco, CA (US);

Inventors:

Han-jie Zhou, Foster City, CA (US);

Congcong M. Sun, Cupertino, CA (US);

Kevin D. Shenk, Palo Alto, CA (US);

Guy J. Laidig, Menlo Park, CA (US);

Assignee:

Onyx Therapeutics, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/06 (2006.01); A61K 31/425 (2006.01); A61K 31/56 (2006.01); A61K 31/535 (2006.01); A61K 31/42 (2006.01); A61K 31/415 (2006.01); A61K 31/38 (2006.01); A61K 31/69 (2006.01); A61K 38/55 (2006.01); C07K 5/062 (2006.01); C07K 5/065 (2006.01); C07K 5/078 (2006.01); C07K 5/083 (2006.01); C07K 5/087 (2006.01); C07K 5/097 (2006.01); C07K 5/117 (2006.01); A61K 45/06 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/06 (2013.01); A61K 31/69 (2013.01); A61K 38/55 (2013.01); A61K 45/06 (2013.01); C07K 5/0606 (2013.01); C07K 5/06026 (2013.01); C07K 5/06034 (2013.01); C07K 5/06078 (2013.01); C07K 5/06139 (2013.01); C07K 5/081 (2013.01); C07K 5/0806 (2013.01); C07K 5/0808 (2013.01); C07K 5/0812 (2013.01); C07K 5/0821 (2013.01); C07K 5/1024 (2013.01); A61K 38/00 (2013.01);
Abstract

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.


Find Patent Forward Citations

Loading…